AXA : Target reached
Entry price | Target | Stop-loss | Potential |
---|
€19.66 |
€17.9 |
€20.7 |
+8.93% |
---|
AXA shares can be expected to top out below the medium term resistance at 20.1 EUR. The timing appears attractive to take advantage of a correction below this level.
Summary● In a short-term perspective, the company has interesting fundamentals.
Strengths● The company shows low valuation levels, with an enterprise value at 0.6 times its sales.
● The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
● This company will be of major interest to investors in search of a high dividend stock.
● Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses● The stock is currently in contact with a medium-term resistance that must be gotten rid of so as to resume the upward trend.
● According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
● The group usually releases earnings worse than estimated.
● Revenue estimates are regularly revised downwards for the current and coming years.
● For the past year, analysts have significantly revised downwards their profit estimates.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.